Establishing minimal clinically important differences for the Pemphigus Disease Area Index

Area of Science:

• Dermatology
• Autoimmune Diseases
• Clinical Research Methodology

Background:

• Pemphigus is a severe autoimmune blistering disease with significant morbidity.
• Accurate assessment of treatment efficacy relies on validated disease severity scores.
• Establishing Minimal Clinically Important Differences (MCIDs) for scores like the Pemphigus Disease Area Index (PDAI) is essential.

Purpose of the Study:

• To determine the MCIDs for both improvement and deterioration of PDAI scores in pemphigus vulgaris (PV) and pemphigus foliaceus (PF).
• To utilize the anchor-based method for calculating MCIDs, employing patient-reported and physician-assessed global measures.

Main Methods:

• The anchor-based method was applied to PDAI scores from 35 pemphigus patients meeting analysis criteria.
• MCIDs were calculated using a 15-point Likert scale and Physician Global Assessment visual analogue scale (PGA-VAS) as anchors.
• Receiver operating characteristic (ROC) curves were used to identify optimal MCID cutpoints based on the Youden Index.

Main Results:

• The MCID for PDAI activity score improvement was determined to be 2.65 points using the 15-point Likert scale and 2.5 points using the PGA-VAS.
• The MCID for PDAI activity score deterioration was consistently 2.5 points for both the 15-point Likert scale and PGA-VAS anchors.
• The 15-point Likert scale anchor yielded a slightly higher correct classification rate for improvement (78.7%) compared to PGA-VAS (78.0%).

Conclusions:

• This study provides the first MCIDs for PDAI scores in pemphigus, addressing a significant knowledge gap.
• The established MCIDs serve as vital benchmarks for clinical trials, treatment evaluations, and research design in pemphigus.
• Future research should investigate potential cross-cultural variations in MCIDs through international collaborations.